The British Paediatric Surveillance Unit (BPSU) started life in 1986 1 . The stimulus for its creation was twofoldÐthe seeming incompleteness of existing passive surveillance systems, reporting various speci®c infection-related conditions; and a growing burden on paediatricians from investigators asking for reports on these and other rare conditions. The unit was therefore conceived as an active surveillance mechanism and an ef®cient way of focusing reporting through a single channel 1 . Its prime owner has been paediatricians, through the British Paediatric Association, which became the Royal College of Paediatrics and Child Health (RCPCH) in 1996, and in whose headquarters the Surveillance Unit of®ce has been based. However, the BPSU also represents a partnership involving other institutionsÐnamely, the Public Health Laboratory Service, the Institute of Child Health (London) and the Scottish Centre for Infection and Environmental Health.
In nearly a decade and a half the unit has been used to undertake over forty studies in the 12±13 million child population of the UK and Eire. These represent over 2100 study-months, detecting over 16 000 cases of rare conditions and contributing wholly or partly to more than one hundred publications in peer-review journals. A measure of its success is imitation, and the BPSU methodology has been adopted by other UK specialties, with surveillance among obstetricians (for HIV), ophthalmologists, specialists in genitourinary medicine (for syphilis), gastroenterologists and neurologists by, respectively, the Royal College of Obstetricians and Gynaecologists 2 , the Royal College of Ophthalmologists 3 , the British Co-operative Clinical Group (genitourinary medicine) 4 , the British Society of Gastroenterology 5 and the British Neurological Surveillance Unit 6 . It has also been imitated abroad, with nine other countries having very similar paediatric units ( Table 1 ) which since 1998 have been in the International Network of Paediatric Surveillance Units 7 . The BPSU serves multiple purposes, allowing paediatricians to undertake and contribute to surveillance but also informing them about rare conditions and responding to public health emergencies such as the advent of variant Creutzfeldt-Jakob disease 8 . The speci®c studies undertaken have covered many areas of child health including infections, metabolic conditions, rare inherited disorders, neurological conditions, accidents and injuries (Box 1). Public health importance has always been one of the prime criteria that the unit's executive committee considers when deciding whether or not to accept a proposal. In this paper we review the public health outputs from studies undertaken through the BPSU and similar units in the UK. Unless stated otherwise, the studies cited have been conducted through the BPSU.
METHODS
The mechanism of the BPSU, outlined in Figure 1 , is described in detail elsewhere 1, 9 . It can be characterized as an ef®cient postal system which allows the simultaneous and ef®cient running of multiple surveillance projects whilst limiting the burden of reporting on individual doctors. The system is active surveillance through monthly distribution of an eye-catching orange card ( Figure 2 ) sent to every paediatrician of consultant status currently seeing patients in the UK or Eire. Their contact details are maintained in an active database in the BPSU of®ce reconciled at intervals with the database of RCPCH members. Through the orange card, respondents are asked whether they have seen any case of up to 14 rare conditions in the preceding month. The card is returned to the BPSU of®ce whether or not one of the conditions has been seen and a remarkable statistic is that, after 14 years, over 90% of doctors still return their orange card to the BPSU every month 10 . Most months, most doctors will make a`nil return', but when the occurrence of a case is reported on a card the BPSU of®ce tells the appropriate investigator the name of the paediatrician concerned. The investigator then sends him or her a data collection proforma (reviewed by the BPSU Executive for brevity, relevance and con®dentiality) for completion. No patient information is passed to the BPSU itself, and the proformas conform to Caldicott principles 11 , capturing only the patient information required to achieve study aims. Increasingly, patient identifying data are anonymizedÐi.e. no names are sent to investigators. Sometimes the elimination of duplicates and linkage of datasets still requires names, but the need will become less as NHS numbers come into wider use. To improve the completeness, accuracy and validity of their data most studies reconcile the detail of the reports with other sourcesÐfor example, laboratory reports for studies on infections.
PUBLIC HEALTH OUTPUTS

Informing policy decisions on screening
An innovation of the 1990s was the establishment of a UK National Screening Committee (NSC) 12 . The initial core job of the NSC has been making decisions on the initiation (or not) of screening for over two hundred conditions proposed as screening candidates in addition to considering the quality and value of existing screening programmes 13 . Dr Muir Gray (the NSC's scienti®c secretary) has characterized this role as`Starting starting, starting stopping, stopping starting and stopping stopping. . . of screening'. Data derived through the BPSU and its equivalents have contributed substantially to those decisions ( Table 2 ). In the 1990s surveillance for paediatric AIDS revealed considerable numbers of children vertically infected with HIV from their mothers, in the UK 14 . For many of these children the development of a lifethreatening AIDS-de®ning condition was seemingly the ®rst occasion that the mother's infection was known about (Figure 3 ). This and the appreciation that it was possible to prevent vertical infection almost entirely (also measurable via the BPSU 15 ) generated pressure for change. The impact was seen ®rst in professional approaches, then in government attitudes and ®nally in the introduction of a 16, 17 . By contrast, surveys for vertically acquired toxoplasmosis and neonatal herpes indicated that the incidence of neonatal disease was too low to justify initiation of screening in pregnancy for either new maternal toxoplasmosis infections or active genital herpes 18, 19 . Surveillance for syphilis in pregnancy (through genitourinary medicine specialists) and congenital syphilis revealed a continuing burden of infectious syphilis in mothers and with other data led to a decision by the National Screening Committee to continue antenatal syphilis screening 4, 20 . BPSU derived data have also informed screening for non-communicable disorders. The physical examination of all newborn and young infants is a long established and universal screening practice in the UK. Two of the main target disorders, congenital dislocation of the hip (CDH) and congenital cataract have both been surveyed through the BPSU, as well as through disorder-speci®c orthopaedic and ophthalmic clinician-based reporting schemes, respectively. The CDH survey showed that the incidence of ®rst operative procedure for CDH has not changed since screening was introduced, and most children requiring surgery do not seem to be detected through the formal screening examination 21 . The cataract survey indicated that less than half of all children newly diagnosed with congenital cataract were detected through the routine newborn or 6±8 week examination intended to detect this disorder. This identi®ed a need for improvements in the routine ophthalmic examination of infants, especially in the training of those responsible 22 . Together these ®ndings have informed NSC recommendations regarding the need to improve the quality of established practice nationally and to consider alternative strategies for improving early detection of both disorders. Surveillance data are also used to monitor screening programmes continuously. Surveillance via the Royal College of Obstetricians and Gynaecologists' system allows the continuous monitoring of the effectiveness of antenatal HIV screening to detect HIV in pregnant women 23 .
Providing information for clinical governance
A survey of children with biliary atresia revealed important differences in outcome for this condition according to the size of the unit undertaking surgery and the number of cases operated upon (with centres handling more cases showing better outcome) 24 . This led to an NHS Executive directive restricting the number of centres where surgery could be undertaken 25 . In contrast a study of water-births was reassuring, yielding no evidence that this practice heightens the risk of mortality or morbidity 26 . A study of Munchausen-syndrome-by-proxy revealed major differences in regional incidence and therefore raised questions of clinician awareness of this condition 27 . Surveillance of Reye's syndrome began in 1981, with a risk factor study showing an association between Reye's syndrome and consumption of aspirin. Findings from this and other studies led to a ban on the use of aspirin in children under 12 years. Subsequent monitoring showed almost total elimination of Reye's syndrome in the UK, at least before the teenage years 28 . 29 ) and reasons why vaccination failed in some children but not others. Surveys for subacute sclerosing panencephalitis (SSPE) (measles vaccination), congenital rubella syndrome (CRS) and invasive Haemophilus in¯uenzae type b (Hib) infection monitor the occurrence of these sentinel conditions. All these reports are strengthened by combination of clinician and laboratory reporting. SSPE reporting indicates that this rare condition results from wild measles, not vaccination 30 . Surveillance for CRS 28 and Hib has indicated the general success of immunization programmes; in the case of Hib it con®rms that the UK's strategy (unique in Europe) of not boosting vaccination around school entry was not prejudicing immunity 31 . The latter study also indicated that, where vaccination failed, many of the children had an underlying predisposing disorder 31 .
Identifying and quantifying public health issues
Several studies have derived estimates of the population incidence of important conditions, as a basis for identifying those at greatest risk, providing services and planning further research on aetiology and treatment. Whilst other approaches (for example, use of data routinely collected through the Of®ce for National Statistics or Hospital Episode Statistics System) can yield simple statistics, the advantage of the BPSU mediated studies is that they ef®ciently capture essential clinical, social and other data, enabling the potential for health gain to be highlighted together with possible aetiological links. Such BPSU mediated studies have proved especially useful for noncommunicable disorders 22,24,32±36 . Various aspects of accidental and non-accidental injury in children, such as poisoning 34 , subdural haematoma 35 and drowning 37 , have been quanti®ed. For example, surveillance for accidental poisoning from toy chemistry sets con®rmed concerns about problematic packaging and led to amendments in European Union legislation on toy safety 34 . Two BPSU surveys identi®ed diabetes mellitus as an increasingly important disorder of childhood with attendant future public health implications, and contributed to hypotheses about aetiology 32 . All these studies of non-communicable disorders have involved analyses that would be impossible without clinician reporting.
Responding to public health emergencies
The ®nal aim of the BPSU has been to respond to public health emergencies. Three examples are water-births, variant Creutzfeldt-Jakob disease (vCJD) and haemorrhagic disease of the newborn (vitamin K de®ciency bleeding). The common feature of these three diseases was a sudden recognition of their potential public health importance and a consequent need to determine their extent. For waterbirths there was concern that a vogue for delivering babies in birthing pools might increase perinatal morbidity and mortality. A surveillance study, combined with a postal survey assessing the extent of the practice, yielded no evidence of increased risk 26 . The emergence of vCJD in young adults in 1996 38 raised a question of whether the condition was occurring in children. This was particularly dif®cult to investigate because the phenotype of vCJD in children was not obvious. Would it be like that in adults, or might it be somewhat different 8 ? The approach taken was to look for all cases of progressive intellectual and neurological deterioration in children and to have an expert group of paediatric neurologists examine anonymized information from the cases. This exercise has con®rmed that, though vCJD does occur in childhood, there is no evidence of an epidemic in children 8 . Haemorrhagic disease in the newborn, a topic previously investigated through the BPSU 39 , required a further look because of changes in practice. For some years there has been concern that injected vitamin K might be associated with an increased incidence of certain cancers of childhood 40 . Further studies did not resolve these concerns 41 , so in the late 1990s oral preparations of vitamin K began to be used in preference to injectables. This raised the possibility of an increased incidence of haemorrhagic disease because of ineffective therapyÐhence the need to repeat the earlier study. All three of these`emergency' investigations were sponsored by the Department of Health.
DISCUSSION
An advantage of the BPSU is that it allows multiple studies to be undertaken simultaneously 1 , at much less cost than a series of individual studies. It is also an ef®cient mechanism for the reporting doctor, who ®lls in just one card per month. Paradoxically, however, surveillance units such as the BPSU have dif®culty in raising money because many funding bodies prefer to support individual studies. Another issue that arises is the competition for places on the small orange card between new short-term studies and ongoing surveillance for important conditions where clinicians are either the only or the most convenient source of data. The scope for continuing and extending the work undertaken through the BPSU and its equivalents is considerable. However, there is one black cloud on the horizon. The Data Protection Act 1998, the common-law duty of con®dence, some guidance from the General Medical Council and the Human Rights Act have raised the notion that doctors should always obtain explicit patient or parental consent before sharing with other health professionals identi®able data required for public health surveillance. On existing evidence, this could mean loss of between 40% and 60% of reports. This is not because of refusals from parents or patients but because of the workload such requirements place on doctors. An example is the combined surveillance and research study undertaken by the RCPCH's Research Unit and the Surveillance Unit of the Royal College of Ophthalmologists on retinopathy of prematurity. Parental consent was necessary because the research phase of the study involved seeking parents' views about the information they were given about the condition. 180 cases were initially reported via a BPSU-like mechanism, and then parental consent had to be obtained. The data collection process was considerably delayed, and initially consent was obtained for only 22% of the cohort.
After a year the proportion with consent was 46% and three months after closure of recruitment it was 62%. There were only 3 cases where parents refused consent. For the 112 cases where consent was obtained it took on average two months, but for 12 cases it took between six and twelve months. Though with further reminders the proportion has risen, this was achievable only because the surveillance study had revealed there were cases to be pursued. Other surveillance and reporting schemes have had similar experiences when consent was required 42 . The BPSU Executive is concerned that, if explicit consent had to be sought from parents before a case was reported to the BPSU, then key information required to protect the health of children would not be obtained in the future. Current examples of conditions for which surveillance would be stopped or severely curtailed are HIV and AIDS, vaccine preventable diseases, rare adverse consequences of vaccination, vCJD, subdural haematoma (commonly a result of child abuse) and haemorrhagic disease of the newborn. Outside of the BPSU system, surveillance for meningococcal disease and haemolytic-uraemic syndrome would be similarly affected. Where we should look for guidance on how to proceed in this important area, so that public health surveillance is not prejudiced, is not yet clear 42 . 
